Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 4/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | USP9X | Q93008 | 1/20 | 0.31 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.31 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.31 |
| ▸ | ITGAL | P20701 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21461907 | 0.92 | HTT (0.36) | HTTMAPTLMNABLMIDO1 | |
| SCHEMBL620776 | 0.83 | MAPT (0.36) | HTTMAPTIDO1MAOBKMT2A | |
| SCHEMBL30203761 | 0.82 | IDO1 (0.34) | HTTMAPTIDO1KMT2ADYRK1A | |
| SCHEMBL11999826 | 0.75 | RAB9A (0.37) | MAPTNPC1RAB9ASMN1; SMN2USP9X | |
| SCHEMBL21603162 | 0.75 | STIM1 (0.33) | MAPTLMNAKMT2ANPC1RAB9A | |
| SCHEMBL23109661 | 0.75 | IDO1 (0.35) | HTTLMNAIDO1TP53USP9X | |
| SCHEMBL16754543 | 0.75 | MAPT (0.41) | MAPTKMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4140066 | 0.75 | USP9X (0.32) | USP9XITGB2ICAM1ITGALRHOA | |
| SCHEMBL618866 | 0.73 | IDO1 (0.34) | HTTIDO1KMT2ADYRK1A | |
| Hydrochloric Acid SCHEMBL31177637 | 0.73 | MAPT (0.44) | MAPTKMT2ANPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 234 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11071725-B2 | Activating pyruvate kinase R | FORMA THERAPEUTICS, INC. (US) | 2021-07-27 | — | — | US | claimed |
| EP-4721737-A1 | USE OF PHARMACEUTICAL COMPOSITION COMPRISING COMPOUND HAVING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE FOR TREATING ANEMIA-RELATED DISEASES | Scinnohub Pharmaceutical Co., Ltd. (CN) | 2026-04-08 | — | — | EP | disclosed |
| US-20260085082-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES, INC. (US) | 2026-03-26 | — | — | US | disclosed |
| US-12528822-B2 | Cycloalkane-1,3-diamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2026-01-20 | — | — | US | disclosed |
| EP-4637760-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | Imago Biosciences Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| EP-4622958-A1 | SYNTHESIS OF PYRROLO[3,4-C]PYRROLES | Novo Nordisk Health Care AG (CH) | 2025-10-01 | — | — | EP | disclosed |
| EP-4617276-A2 | PYRUVATE KINASE R (PKR) ACTIVATING COMPOSITIONS | Novo Nordisk Health Care AG (CH) | 2025-09-17 | — | — | EP | disclosed |
| EP-4031133-B1 | PYRUVATE KINASE R (PKR) ACTIVATING COMPOSITIONS | NOVO NORDISK HEALTHCARE AG (CH) | 2025-08-13 | — | — | EP | disclosed |
| US-20250145635-A1 | COMPOUND CONTAINING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE AND USE THEREOF IN MEDICINE | SCINNOHUB PHARMACEUTICAL CO., LTD. (CN) | 2025-05-08 | — | — | US | disclosed |
| US-20250099481-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. | 2025-03-27 | — | — | US | disclosed |
| US-6455554-B1 | COMPOUNDS CAPABLE OF AFFECTING NICOTINIC CHOLINERGIC RECEPTORS; TREATOMG CENTRAL NERVOUS SYSTEM DISORDERS | TARGACEPT, INC. | 2002-09-24 | — | — | US | disclosed |
| US-6432954-B1 | CENTRAL NERVOUS SYSTEM DISORDERS | TARGACEPT, INC. | 2002-08-13 | — | — | US | disclosed |
| EP-1225955-A1 | ARYL OLEFINIC AZACYCLIC, AND ARYL ACETYLENIC AZACYCLIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE AS INHIBITORS OF NICOTINIC CHOLINERGIC RECEPTORS | Targacept, Inc. (US) | 2002-07-31 | — | — | EP | disclosed |
| WO-2002056882-A1 | QUINOLINES AND NITROGENATED DERIVAIVE THEREOF SUBSTITUTED IN 4-POSITION BY A PIPERIDINE-CONTAINING MOIETY AND THEIR USE AS ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-07-25 | — | — | WO | disclosed |
| US-20020058652-A1 | Pharmaceutical compositions and methods for use | TARGACEPT, INC. | 2002-05-16 | — | — | US | disclosed |
| EP-1185514-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | Targacept, Inc. (US) | 2002-03-13 | — | — | EP | disclosed |
| WO-2002005801-A2 | COMPOSITIONS CONTAINING DIACYLTARTARIC SALTS OF (E)-METANICOTINE | TARGACEPT, INC. (US) | 2002-01-24 | — | — | WO | disclosed |
| WO-2002005798-A2 | PHARMACEUTICAL COMPOSITIONS FOR TREATING NEUROLOGICAL DISORDERS | TARGACEPT, INC. (US) | 2002-01-24 | — | — | WO | disclosed |
| WO-2001032264-A1 | ARYL OLEFINIC AZACYCLIC, AND ARYL ACETYLENIC AZACYCLIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE AS INHIBITORS OF NICOTINIC CHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2001-05-10 | — | — | WO | disclosed |
| WO-2000075110-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | TARGACEPT, INC. (US) | 2000-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058652-A1 | Pharmaceutical compositions and methods for use | CYP3A7, AADAC, CYP2B6 | HTT 1097/4885MAPT 2733/4885LMNA 1971/4885 |
| US-20250099481-A1 | BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L10 | HTT 3033/4885MAPT 4367/4885LMNA 893/4885 |
| US-20250145635-A1 | COMPOUND CONTAINING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE AND USE THEREOF IN MEDICINE | BCL9, USP9X, BCL9L | HTT 2375/4885MAPT 3783/4885LMNA 1053/4885 |
| US-20260085082-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | KDM1B, KDM1A, KDM5C | HTT 1761/4885MAPT 2266/4885LMNA 597/4885 |
| US-11071725-B2 | Activating pyruvate kinase R | PCK1, PDK1, GCKR | HTT 3131/4885MAPT 2180/4885LMNA 1465/4885 |
| US-12528822-B2 | Cycloalkane-1,3-diamine derivative | MLLT1, MLLT3, PRMT6 | HTT 4310/4885MAPT 3711/4885LMNA 1233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.